Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 18, 2019. The report discloses transactions involving Persons Discharging Managerial Responsibilities (PDMRs) selling shares to meet tax liabilities following the vesting of awards granted in 2016 under the Company's 2009 Performance Share Plan.
Key Financial Metrics
The filing does not provide company-wide financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on specific share transactions.
| Transaction Date | Instrument | Price | Total Volume |
|---|---|---|---|
| February 15, 2019 | Ordinary Shares (GBP) | £15.8462 | 211,920 |
| February 15, 2019 | American Depositary Shares (USD) | $41.1716 | 18,986 |
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It solely documents routine compliance transactions related to executive compensation vesting.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. The transactions were executed on the London Stock Exchange (XLON) and the New York Stock Exchange (XNYS) to satisfy tax obligations.
Investor Verification Checklist
- Verify the total number of shares sold by PDMRs to ensure alignment with the 2016 Performance Share Plan vesting schedule.
- Confirm the transaction prices (£15.8462 and $41.1716) against market closing prices on February 15, 2019.
- Review the Company's Form 20-F for comprehensive financial performance data, as this 6-K does not contain earnings or balance sheet information.